Clinical value of simultaneous detection of anti-dsDNA and anti-chromatin antibodies using a multiplex immunoassay in systemic lupus erythematosus: a 5-year retrospective study (12 January, 2026) ...
Objective To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis (LN) represents a real-world SLE cohort. Methods Literature reviews were performed of major ...
Objectives To evaluate the performance of Systemic Lupus Erythematosus Risk Probability Index (SLERPI) in patients with SLE using a Chinese cohort. Methods The Chinese cohort included 352 patients ...
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.
Objectives Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (SLE) in China. However, the economic value of these two drugs is unclear. Therefore, this ...
Objectives To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and ...
Objectives The impact of corticosteroids on the risk of organ damage in the context of clinical end points endorsed in some systemic lupus erythematosus (SLE) clinical trials is underexplored. Methods ...
Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease driven by pathological autoreactive T and B lymphocytes. Sphingosine 1-phosphate (S1P) regulates the egress of T and B ...
Objective This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment. Methods Patients with proliferative±membranous LN ...
Background Daxidilimab (DAX) is an IgG1λ afucosylated monoclonal antibody specific for immunoglobulin-like transcript 7 (ILT7), a cell-surface protein that is exclusively expressed on plasmacytoid ...
LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback